George Medicines' Widaplik FDA Approval: Breakthrough Triple Combo for Hypertension

Highlights

• FDA approves Widaplik, the first triple-combination pill for hypertension use as initial therapy.
• Widaplik combines telmisartan, amlodipine, and indapamide with three dosing options.
• Late-stage trials show Widaplik outperforms placebo and dual-drug combos in blood pressure control.
• U.S. launch planned for Q4 2025, with further regulatory submissions forthcoming.
• Approximately 119 million U.S. adults have hypertension; only 25% manage it effectively.
• FDA boxed warning advises stopping Widaplik during pregnancy due to fetal toxicity.
• George Medicines is also testing Widaplik for improving outcomes after intracerebral hemorrhage stroke.

FDA Approves Widaplik as a Novel Triple-Combination Therapy

George Medicines has received approval from the U.S. Food and Drug Administration (FDA) for Widaplik, a groundbreaking three-in-one pill designed to treat hypertension. This innovative medication combines three established blood pressure drugs—telmisartan, amlodipine, and indapamide—into a single formulation. Widaplik is notable for being the first triple-combination therapy approved by the FDA for use as an initial treatment, addressing the needs of patients likely requiring multiple medications to reach their blood pressure targets.

Dosing Options and Clinical Trial Outcomes

Widaplik offers three dosing options, including one low dose and two standard doses, which enable an early introduction of triple therapy while maintaining a proven safety profile and good tolerability. According to a June 9 press release from George Medicines, the medication provides the benefits of combining three antihypertensive agents "early in the treatment pathway."

In late-stage clinical trials, Widaplik was compared against placebo and dual-drug combinations of its component medicines. The triple-combination pill demonstrated superior efficacy by significantly improving patients' blood pressure control rates over the other tested regimens.

Market Plans and the Hypertension Challenge

The U.K.-based biopharmaceutical company is targeting a U.S. launch for Widaplik in the fourth quarter of 2025, with plans to submit additional regulatory applications within the year. The FDA reports that approximately 119 million adults in the United States suffer from high blood pressure, yet only about 25% have their condition adequately managed. This "silent killer" is a major contributor to heart disease, heart failure, and strokes despite often presenting without symptoms.

Mark Mallon, CEO of George Medicines, stated, “Data show that most patients with hypertension will require two or more medicines to bring their blood pressure under control. Widaplik can provide patients with hypertension, including those who are starting treatment, with a different approach to control their blood pressure.”

Safety and Additional Indications

Widaplik carries an FDA boxed warning advising patients to discontinue the medication promptly upon confirmation of pregnancy due to fetal toxicity risks. Beyond hypertension, George Medicines is exploring the potential of Widaplik to reduce mortality and disability in patients suffering intracerebral hemorrhage, a serious form of stroke caused by bleeding within the brain. Early data from an ongoing Phase 3 trial indicate that this triple-combination therapy can significantly improve survival rates without major disabilities in such patients.